Generate Biomedicines (NASDAQ:GENB) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research note issued to investors on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $16.00 price objective on the stock.

Several other research analysts also recently weighed in on GENB. Morgan Stanley assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating and a $20.00 target price for the company. Guggenheim assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price objective for the company. Zacks Research raised Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Wall Street Zen raised Generate Biomedicines to a “hold” rating in a research note on Saturday, March 14th. Finally, Piper Sandler assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.20.

Generate Biomedicines Trading Up 12.2%

Shares of GENB stock opened at $12.80 on Monday. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.